Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AADI NASDAQ:CCCC NASDAQ:EPRX NASDAQ:RZLT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAADIAadi Bioscience$4.16+2.5%$4.10$1.21▼$3.81$102.74M0.68261,100 shs161,368 shsCCCCC4 Therapeutics$3.90$3.28$1.36▼$4.60$431.22M2.912.26 million shs2.85 million shsEPRXEupraxia Pharmaceuticals$6.04$6.97$3.85▼$9.32$392.72M0.98295,878 shs141,123 shsRZLTRezolute$4.00$3.46$1.07▼$11.46$385.16M0.681.83 million shs1.31 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAADIAadi Bioscience0.00%+0.24%-18.43%+6.39%+112.24%CCCCC4 Therapeutics0.00%+1.30%+9.55%+42.86%+132.14%EPRXEupraxia Pharmaceuticals0.00%+1.51%-12.72%-18.27%+56.48%RZLTRezolute0.00%-5.88%+19.76%+60.64%-4.76%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAADIAadi Bioscience$4.16+2.5%$4.10$1.21▼$3.81$102.74M0.68261,100 shs161,368 shsCCCCC4 Therapeutics$3.90$3.28$1.36▼$4.60$431.22M2.912.26 million shs2.85 million shsEPRXEupraxia Pharmaceuticals$6.04$6.97$3.85▼$9.32$392.72M0.98295,878 shs141,123 shsRZLTRezolute$4.00$3.46$1.07▼$11.46$385.16M0.681.83 million shs1.31 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAADIAadi Bioscience0.00%+0.24%-18.43%+6.39%+112.24%CCCCC4 Therapeutics0.00%+1.30%+9.55%+42.86%+132.14%EPRXEupraxia Pharmaceuticals0.00%+1.51%-12.72%-18.27%+56.48%RZLTRezolute0.00%-5.88%+19.76%+60.64%-4.76%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAADIAadi Bioscience 0.00N/AN/AN/ACCCCC4 Therapeutics 2.57Moderate Buy$7.7598.72% UpsideEPRXEupraxia Pharmaceuticals 2.89Moderate Buy$18.33203.53% UpsideRZLTRezolute 2.64Moderate Buy$8.75118.75% UpsideCurrent Analyst Ratings BreakdownLatest AADI, CCCC, RZLT, and EPRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026RZLTRezolute Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral6/3/2026RZLTRezolute CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform6/3/2026RZLTRezolute Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$11.006/3/2026RZLTRezolute WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$5.00 ➝ $6.006/2/2026RZLTRezolute BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $6.006/2/2026RZLTRezolute Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $14.006/2/2026RZLTRezolute HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.005/21/2026EPRXEupraxia Pharmaceuticals Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$25.005/14/2026RZLTRezolute Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$4.00 ➝ $10.005/7/2026EPRXEupraxia Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/4/2026EPRXEupraxia Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.00(Data available from 6/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAADIAadi Bioscience$25.07M4.10N/AN/A$4.29 per share0.97CCCCC4 Therapeutics$35.95M12.00N/AN/A$2.65 per share1.47EPRXEupraxia PharmaceuticalsN/AN/AN/AN/A$1.41 per shareN/ARZLTRezoluteN/AN/AN/AN/A$1.86 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAADIAadi Bioscience-$65.76M-$2.35N/AN/AN/A-246.06%-71.87%-57.28%N/ACCCCC4 Therapeutics-$104.99M-$1.19N/AN/AN/A-297.76%-50.68%-33.22%8/6/2026 (Estimated)EPRXEupraxia Pharmaceuticals-$38.58M-$1.05N/AN/AN/AN/A-87.56%-51.20%8/11/2026 (Estimated)RZLTRezolute-$74.41M-$0.82N/AN/AN/AN/A-58.82%-54.48%N/ALatest AADI, CCCC, RZLT, and EPRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026CCCCC4 Therapeutics-$0.2506-$0.20+$0.0506-$0.20$4.42 million$6.15 million5/12/2026Q1 2026EPRXEupraxia Pharmaceuticals-$0.22-$0.23-$0.01-$0.23N/AN/A5/12/2026Q3 2026RZLTRezolute-$0.1686-$0.16+$0.0086-$0.16N/AN/A3/19/2026Q4 2025EPRXEupraxia Pharmaceuticals-$0.16-$0.37-$0.21-$0.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAADIAadi BioscienceN/AN/AN/AN/AN/ACCCCC4 TherapeuticsN/AN/AN/AN/AN/AEPRXEupraxia PharmaceuticalsN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAADIAadi BioscienceN/A4.894.54CCCCC4 TherapeuticsN/A9.009.00EPRXEupraxia Pharmaceuticals0.0219.3119.31RZLTRezoluteN/A15.8415.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAADIAadi Bioscience52.08%CCCCC4 Therapeutics78.81%EPRXEupraxia PharmaceuticalsN/ARZLTRezolute82.97%Insider OwnershipCompanyInsider OwnershipAADIAadi Bioscience37.30%CCCCC4 Therapeutics5.60%EPRXEupraxia PharmaceuticalsN/ARZLTRezolute14.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAADIAadi Bioscience4024.70 million15.49 millionNo DataCCCCC4 Therapeutics150110.57 million104.38 millionOptionableEPRXEupraxia Pharmaceuticals2965.02 millionN/AN/ARZLTRezolute4096.29 million82.06 millionOptionableAADI, CCCC, RZLT, and EPRX HeadlinesRecent News About These CompaniesRezolute (NASDAQ:RZLT) Stock Rating Lowered by Wall Street ZenJune 14 at 1:04 AM | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Rezolute (RZLT) and Vericel (VCEL)June 12 at 3:30 PM | theglobeandmail.comPositive Signs As Multiple Insiders Buy Rezolute StockJune 10, 2026 | finance.yahoo.comWall Street Zen Upgrades Rezolute (NASDAQ:RZLT) to HoldJune 6, 2026 | americanbankingnews.comRezolute, Inc. (NASDAQ:RZLT) Receives Average Recommendation of "Moderate Buy" from BrokeragesJune 5, 2026 | americanbankingnews.comRZLT Stock on the Move: What Sparks the 38% Jump in the Past Week?June 4, 2026 | zacks.comRezolute, Inc. Announces Four Presentations at the 2026 Annual Meeting of the Endocrine Society on Ersodetug for Congenital HyperinsulinismJune 4, 2026 | quiverquant.comQRezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine SocietyJune 4, 2026 | globenewswire.comRezolute (NASDAQ:RZLT) Price Target Raised to $6.00 at WedbushJune 4, 2026 | americanbankingnews.comRezolute (NASDAQ:RZLT) Upgraded by Citizens Jmp to "Outperform" RatingJune 4, 2026 | americanbankingnews.comAnalysts Are Bullish on These Healthcare Stocks: Rezolute (RZLT), Relay Therapeutics (RLAY)June 3, 2026 | theglobeandmail.comRezolute upgraded at Citizens after late-stage trial data for lead assetJune 3, 2026 | seekingalpha.comRezolute rises after late-stage trial updateJune 3, 2026 | msn.comRezolute Highlights Strong Early Response Trends In Rare Hypoglycemia Disease StudyJune 2, 2026 | benzinga.comRezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor HyperinsulinismJune 2, 2026 | globenewswire.comRezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business UpdateMay 12, 2026 | globenewswire.comRezolute to Participate in Upcoming Investor ConferencesMay 11, 2026 | globenewswire.comRezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society ...May 1, 2026 | markets.businessinsider.comRezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual MeetingMay 1, 2026 | globenewswire.comRezolute, Inc. Investigated by the Portnoy Law FirmApril 24, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAADI, CCCC, RZLT, and EPRX Company DescriptionsAadi Bioscience NASDAQ:AADI$4.16 +0.10 (+2.46%) As of 06/12/2026Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.C4 Therapeutics NASDAQ:CCCC$3.90 0.00 (0.00%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$3.93 +0.03 (+0.79%) As of 06/12/2026 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Eupraxia Pharmaceuticals NASDAQ:EPRX$6.04 0.00 (0.00%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$6.04 0.00 (0.00%) As of 06/12/2026 05:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.Rezolute NASDAQ:RZLT$4.00 0.00 (0.00%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$3.94 -0.06 (-1.58%) As of 06/12/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Viasat's Orbiting Profits: Space Force Jackpot? What to Expect From Q2 Earnings as Tech Strength Broadens ERock IPO: A $1.3B Power Play Solution TJX: Retail’s Apex Predator Feasts on Inflation Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
